Edessa Tirzepatide Review: $239 a Month, and the $135 Is a Different Drug (2026)

Edessa charges $239 a month for compounded tirzepatide month to month, $219 on a three-month plan and $209 on six. The first line of its homepage says "Start for just $135" — that is a six-month prepay on the semaglutide injection, a different drug at a different term.¹ Read live on 13 September 2026.

Every card on the homepage is a six-month rung

The three product cards read "Starting at $135" for GLP-1 injections, "Starting at $199" for GLP-1 tablets and "Starting at $209" for tirzepatide injections. All three are the six-month figure. The month-to-month rates — $179, $229 and $239 — appear only after a click, on the product page's "PLAN / PER MONTH" table. A reader who compares Edessa's front page against a competitor's monthly rate is comparing a six-month prepay against a month — and RX Bella plays the same trick with a different lever, quoting its cheapest product rather than its cheapest term.

What the product page does well

Click through and the disclosure improves considerably. The table is plain — three rungs, one column of per-month figures, no asterisks — and the page states "Same price, every dose", unlimited 24/7 support, no hidden fees, no insurance required and HSA/FSA eligibility. The "What you get" list names the board-certified provider consultation, the medication, free expedited shipping, ongoing check-ins and dosage adjustments, and clinical support access. It also prints the compounding disclaimer directly under the product image.

Two corporate forms, one clause

Its Terms of Use open: *"The terms 'we', 'us', 'our' and 'Edessa' refer to Edessa Group, LLC, a Nevada corporation located at 732 S 6TH ST STE N, Las Vegas, NV, 89101."*² An LLC is not a corporation — those are two different entity types under Nevada law — and the sentence gives both for the same company in the same breath. Publishing an entity and a street address at all puts Edessa ahead of Prime Doctor RX, whose Terms name no company whatsoever. It just does not quite know what it is.

Two claims with nothing behind them

"Join 100,000+ successful GLP-1 patients" runs across the homepage in a scrolling bar with no source attached. And a "Weight Loss Money-Back Guarantee" is advertised in the hero and in the benefits grid — "If you don't see results, we'll refund your purchase no questions asked" — but its terms are not on any marketing page, so what qualifies as not seeing results is unstated. Renlo Health publishes a comparable guarantee with its conditions attached.

A smaller tell: the homepage's own `<title>` element is literally "Home".

The brand-vs-compounded question

This is compounded tirzepatide, not Zepbound or Mounjaro, and the product page says so: compounded products are not approved or evaluated for safety, efficacy or quality by the FDA. Our guide to whether compounded tirzepatide is still legal in 2026 covers where that stands.

Does the drug work? (Separate from the provider)

Pricing is the seller's problem; efficacy is the molecule's. SURMOUNT-1 put weight loss at roughly 15% to 21% of body weight over 72 weeks³, and SURMOUNT-5 placed it ahead of semaglutide head to head⁴, both on the approved brand product. Our tirzepatide evidence guide has the full picture.

The honest verdict

The product page is better than the homepage that leads to it: a clean three-rung table, a flat-dose promise, an all-in inclusions list and a published address. The homepage is the problem — three cards all quoting six-month rungs, with the very cheapest one belonging to a different molecule. Budget $239 unless you are prepaying six months. If you want the ladder and the pharmacy both named, No BS RX publishes four dispensing addresses; if you want a monthly figure that needs no decoding at all, Renlo Health charges $269 billed monthly. The ranked best tirzepatide providers list sets them against the field.